Using a special nanodrug to treat breast cancer spread in animals
anti-miR-10b Nanodrug for Treatment of Breast Cancer Metastasis: Study in Companion Animals
This study is testing a new type of treatment that uses tiny particles to deliver a special drug directly to hard-to-reach areas of metastatic breast cancer, with the hope of making these cancer cells less able to survive and grow, which could help improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10875289 on NIH RePORTER |
What this research studies
This research investigates a novel nanodrug designed to target and inhibit a specific microRNA (miR-10b) that is crucial for the survival of metastatic breast cancer cells. By using dextran-coated magnetic nanoparticles, the researchers aim to deliver anti-miR-10b directly to metastatic sites in a large animal model, allowing for precise targeting and monitoring through magnetic resonance imaging (MRI). The study focuses on understanding how effectively this approach can reduce the viability of metastatic cells, which is a significant cause of mortality in breast cancer patients. If successful, this could lead to new treatment strategies for breast cancer metastasis.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic breast cancer, particularly those whose tumors express high levels of miR-10b.
Not a fit: Patients with early-stage breast cancer or those whose tumors do not express miR-10b may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new targeted therapy for patients with metastatic breast cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise with nanoparticle-based therapies in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Moore, Anna — Michigan State University
- Study coordinator: Moore, Anna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.